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goal, the proportion of and time to A1C increasing above 7% (relapse) were ana-
lyzed. Cox proportional hazard models were estimated to identify demographic
and clinical predictors of A1C goal achievement and relapse. RESULTS: Basal insu-
lin initiators with T2DM (n13,373) were on average 60 years old, 50.5% were fe-
males, 59.5% had A1C8%, 59.7% were obese, and more than half used metformin
(52.7%) or sulfonylureas (53.4%) before insulin initiation. A total of 5844 (44%) pa-
tients reached goal within one year since initiation, and 7699 (58%) reached goal
during the 2.5-year follow-up. The median time to reaching goal was 536 days
(95% CI: 510-562). Older age, being white or male, lower baseline A1C values and no
OAD use before insulin initiation were associated with significantly higher rates of
reaching goal. Among the patients who reached goal, 57.6% relapsed, and the me-
dian time from reaching the goal to relapse was 398 days (95% CL: 383-417). Being
Hispanic, higher baseline A1C values and OAD use at baseline were associated with
significantly higher rates of relapse. CONCLUSIONS: A high proportion of T2DM
patients did not have adequate glycemic control after initiating basal insulin. Var-
ious factors existing prior to insulin initiation were related to successful treatment
of T2DM. Further research into how to improve glycemic control is encouraged.
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OBJECTIVES: The aim of the current study was to examine patient characteristics,
treatment patterns, and burden of type 2 diabetes (T2D) adult patients with and
without comorbid obesity in France, Germany, and UK. METHODS: Data from the
EU National Health and Wellness Survey were used. Demographics, HbA1c levels,
prevalence of hypertension, high cholesterol, T2D current treatments, and health
outcomes (SF-12) were assessed for all T2D patients (France: n642, Germany:
n1,019, UK: n932). Patients with and without obesity (BMI30) were also
compared. RESULTS: Obesity rates within T2D were 47%, 51%, and 56% in France,
Germany, and UK, respectively. Pooling countries, T2D patients had 2.6 greater
odds of obesity than non-T2D patients and the proportion of obese T2D patients
increased from 44% to 51 % (2006 to 2010). The rates of being uncontrolled (HbA1c
7%) were higher among obese T2D (20% vs. 17%, p.05), but the difference was
only significant in Germany (24% vs. 19%, p.05). The use of insulin was signifi-
cantly higher (23% vs. 16%, p.05) among obese patients, but this difference was
only significant in Germany and UK and not in France. Hypertension and high
cholesterol were significantly more prevalent in obeseT2D patients (65% vs. 51%
and 40% vs. 35%, respectively, ps.05). Hypertension differences were significant
for all countries while high cholesterol differences were only significant in Ger-
many. Obesity was associated with significantly worse physical quality of life
(France: 40 vs. 44; Germany: 39 vs. 44; UK: 37 vs. 42, respectively p.05).
CONCLUSIONS: A substantial number of T2D patients are obese. Obesity was as-
sociated with worse quality of life, and worse health outcomes including poor
glycemic control (in the case of Germany), hypertension and high cholesterol; all
these factors are CV disease risk factors. Improving obesity management will be
the key to improve health and outcomes in T2D.
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OBJECTIVES: We analyzed the impact of implementing a preauthorization policy
for Rosiglitazone (an anti-diabetic drug) use on the eligibility requirements (treat-
ment initiation and discontinuation) and patients’ HbA1c levels. METHODS: We
compared treatment patterns of diabetic patients prior to and after an implemen-
tation of a preauthorization policy for Rosiglitazone use. Data were obtained from
the Maccabi Healthcare Services’ (the second largest HMO in Israel) registry of
diabetic patients. We compared adherence to eligibility criteria in a group of pa-
tients who received Rosiglitazone without preauthorization (N1362) and patients
who received the medication with preauthorization (N824). The criteria for re-
ceiving Rosiglitazone in both groups were identical and included prior medication
[experienced patients who received drug from the sulphonylurea class in combi-
nation with Metformin for at least a three months period], and laboratory criterion
[HbA1c levels higher than 8% during the past three months]. Treatment should be
continued only if within three months from treatment initiation, the patient ac-
quired at least three packages of Rosiglitazone and a decrease of 0.8% in HbA1c
values was observed. RESULTS: Implementing preauthorization policy increased
the fulfillment of the eligibility criteria (medication and laboratory) for drug use by
41% [from 25% of patients without preauthorization to 35% with preauthorization
(p0.001)]. With regard to meeting the requirements for treatment continuation
after a three month period, there was an increase of only 6.4% in the fulfillment of
both requirements (from 37.6% to 40.0% prior and after preauthorization, respec-
tively). The average decrease in patients’ HbA1c levels was 0.6% and was similar in
both patients with and without preauthorization. CONCLUSIONS: Implementing
preauthorization for Rosigitazone resulted in an increase in meeting the require-
ments for treatment initiation and a marginal change in treatment continuation
criteria, but this increase was insufficient to achieve HbA1c target levels. However,
patients’ health was not negatively affected by this policy.
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OBJECTIVES: Type 2 diabetes, is a disease with a rising prevalence worldwide. A
major burden of this disease would be shared by developing countries like Iran.
Medications for diabetes mellitus need to be taken for the entire life and factors like
efficacy, side effects, drug interactions and cost of therapy should be consider. This
study was designed to evaluate the prescription pattern of anti-diabetic drugs in
T2DM patients from 2006 to 2009 in Iran. METHODS: A retrospective study was
undertaken on insured prescriptions during 4 years. All insured prescriptions
which were collected in special software called Rx Analyst during the study period
in the NCRUD were reviewed for prescriptions included anti-diabetic drugs. The
brand names of drugs in prescriptions were decoded to generic names, according to
standard Iran drug list.RESULTS:A total of 261,110,666 prescriptions were assessed
in which 11,637,224 were detected to be included at least one dosage form of anti-
diabetic medications. From all, 1,376,750 prescriptions had at least one injection
form of Insulin and 10,260,474 of oral anti diabetic drugs. Trend evaluation of
prescribing showed that the total number anti-diabetic medications were in-
creased from 16,158,375 in 2006 to 4,268,444 in 2009. The portion of prescriptions
with Insulin was 8%, 9%, 13% and 9% and for oral anti-diabetic drugs, it was 59%,
66%, 71% and 72%in 2006, 2007, 2008 and 2009, respectively. The total cost of Insulin
during study period was 17,134,032 US$ and for oral anti-diabetic drugs was
84,682,039 US$ from national sales data. CONCLUSIONS: According to national
sales data, total cost of anti-diabetic medications is about 100,00 times more than
cost of these drugs in prescriptions. This huge gap shows irrational use of such
medications. A multi interventional policy including educational, regulatory, man-
agerial and financial strategies for professions and public should be planed to
promote rational use of anti-diabetic medications.
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OBJECTIVES: To evaluate the distribution of pioglitazone (PIO) daily dose pre-
scribed by physicians for patients with type 2 diabetes mellitus (T2DM).METHODS:
In a retrospective cohort study using the UK MediPlus database, patients with
diagnosed T2DM who received PIO prescription between July 2008– June 2009 (ob-
servation period) were included. Medical records from 07/2007–06/2008 were used
to assess baseline conditions. Patients were grouped, according to prescriptions in
the observation period, as low-dose users who received PIO prescriptions of 15-mg
daily dose only or were down-titrated to 15 mg from a higher daily dose, and
high-dose users for the rest who received a 30 mg or higher daily dose. RESULTS:Of
1813 patients with T2DM who received a PIO prescription, 48% received at least one
15 mg prescription during the observation period. Among all PIO prescriptions,
39%, 40%, and 21% were in 15, 30, and 45 mg or higher daily dose, respectively. Per
study definitions 38% of the patients were classified as low-dose users and 62% as
high-dose users. Low-dose users were more likely to be female (56% vs. 40%) and
had a lower baseline prevalence of diabetic nephropathy (0% vs. 1%), compared to
high-dose users (p0.05). Low-dose PIO use was not associated with baseline prev-
alence of congestive heart failure, coronary artery disease, or bone fractures.
CONCLUSIONS: Low-dose PIO was prescribed in greater than one-third of PIO pre-
scriptions, regardless of patient age and major comorbidities. The reason(s) why
patients received low-dose PIO warrants further investigation.
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OBJECTIVES: This retrospective study compares annual expenditures among
T2DM patients according to treatment stage and renal function status (RFS) and
identifies determinants of costs.METHODS:T2DM patients’ records were extracted
from the EGB database, which contains ambulatory care claims for a representative
sample of the French population. Patients were classified according to treatment
stage: oral / GLP1 monotherapy, double therapy, triple therapy or insulin therapy
(either associated or not with other antidiabetics), and according to RFS (identified
using pharmacy, lab and consultation claims). Costs were estimated from the na-
tional insurance perspective and included all reimbursements except for hospitali-
sations. Annual expenditures were assessed by year (from 2005 to 2010), by treat-
ment stage and by RFS. Effects of treatment stages and RFS on expenditures by year
were analysed by means of generalised linear models, with matching on age and
gender. RESULTS: The number of patients ranged from 9,682 to 11,772 between
2005 and 2010. Annual average total reimbursements in 2010 were €3,279 (standard
error: 65.5) for monotherapy, €3,592 92.1 for double therapy, €3,803 157.2 for
triple therapy and €7,729 180.8 for insulin therapy. The same cost pattern was
found in previous years. The regression model showed that costs increased by a
ratio of 2.31 (p0.001) from monotherapy to insulin therapy, adjusted for socio-
demographic characteristics and co-treatments. Excess costs for insulin therapy
were mainly related to nursing care (increasing by a ratio of 12.16, p0.001), med-
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